1. Pink Sheet
  2. >>Market Access

What Will USPTO-FDA Collaboration Look Like? Stakeholders To Weigh In On Proposed Initiatives

 
• By Brenda Sandburg

Agencies are holding public ‘listening session’ to get input on method of use patents and ‘skinny labeling,’ REMS patenting, PTAB proceedings and other topics.

FDA and USPTO
USPTO and FDA holding public meeting to get input on areas for collaboration • Source: Nielsen Hobbs; the Pink Sheet|Shutterstock images

The US Patent and Trademark Office and US Food and Drug Administration are working out how they will collaborate to promote greater access to medicines and increase competition. Industry representatives, patients, payors and other stakeholders will get a chance to provide feedback on potential actions the agencies may take to achieve this goal.

The agencies are holding a public “listening session” on 19 January to obtain input on their joint collaboration initiatives. The...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

More from Pink Sheet

Semaglutide: EMA Safety Probe Confirms Rare Eye Disorder Risk

 
• By Neena Brizmohun

The EU product information for Novo Nordisk’s semaglutide medicines is to be updated to include non-arteritic anterior ischemic optic neuropathy as a side effect with a frequency of “very rare.”

Infographic: Leqembi – A Geographical Comparison

 
• By Anabel Costa-Ferreira

The Pink Sheet explores how regulatory approvals for Leqembi differ around the world, and looks at what is coming next.

EU Pharma Reform: Council Proposal A ‘Step In The Right Direction’ But ‘More Work To Be Done’

 
• By Eliza Slawther

Experts from EUCOPE explain why the Council of the EU’s position on the proposed overhaul of the general pharmaceutical legislation could offer more predictability for companies than the commission’s initial offering.